A Trial of HRS-1893 in Patients With Obstructive Hypertrophic Cardiomyopathy

A Multicenter, Randomized, Open-label Phase II Clinical Study on the Efficacy and Safety of HRS-1893 in Obstructive Hypertrophic Cardiomyopathy Subjects.

The study is being conducted to evaluate the efficacy, and safety of HRS-1893 for obstructive hypertrophic cardiomyopathy

Inclusion Criteria:

1. Age 18-85 years old, gender unlimited;
2. The diagnosis was obstructive hypertrophic cardiomyopathy.
3. Echocardiographic laboratory tests showed LVEF≥60%;
4. No previous left ventricular systolic dysfunction at any time (LVEF < 45%);
5. Understand the study procedure and sign the informed consent in person, willing to strictly follow the clinical study protocol to complete the study.

Exclusion Criteria:

1. Known or suspected invasive, genetic or storage diseases (e.g. Noonan syndrome, Fabre's disease, amyloidosis) that cause cardiac hypertrophy (similar to oHCM);
2. Previous left ventricular systolic dysfunction at any time in the clinical course (LVEF < 45%);
3. Previous history of aortic stenosis or subaortic fixed stenosis;